The goal of the proposed iAβ depletion therapy at the symptomatic stages of AD is to bring iAβ levels below the T1 threshold, the iAβ level required for the activation of the AβPP-independent iAβ production pathway. The gene discussed is APP; the disease is Alzheimer disease.